Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5154-5161

  Bardella, Chiara ^a   Costa, Barbara ^a   Maggiora, Piera ^a   Patane, Salvatore ^a   Olivero, Martina ^a   Ranzani, Guglielmina N ^b   De Bortoli, Michele ^a   Comoglio, Paolo M ^a   Di Renzo, Maria Flavia ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Laboratory of Cancer Genetics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UVOMORULIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; LEUKEMIA; LIGAND BINDING; LUNG PARENCHYMA; MONOLAYER CULTURE; OVARY CARCINOMA; OVARY CELL; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; REPRESSOR GENE; RNA ANALYSIS; TRANSCRIPTION REGULATION; TUMOR GROWTH;

CADHERINS; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPITHELIAL CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; LUCIFERASES; NEOPLASMS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION; SUPPRESSION, GENETIC; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 3442901352     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0600     Document Type: Article

References (41)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature (Lond) 2001;411:355-65.
2. Iwama A, Okano K, Sudo T, Matsuda Y, Suda T. Molecular cloning of a novel receptor tyrosine kinase gene, STK derived from enriched hematopoietic stem cells. Blood 1994;83:3160-9.
3. De Maria R, Maggiora P, Biolatti B, et al. Feline STK gene expression in mammary carcinomas. Oncogene 2002;21:1785-90.
4. Huff JL, Jelinek MA, Borgman CA, Lansing TJ, Parsons JT. The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proc Natl Acad Sci USA 1993;90:6140-4.
5. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev Cancer 2002;2:289-300.
6. Leonard EJ, Danilkovitch A. Macrophage stimulating protein. Adv Cancer Res 2000;77:139-67.
7. Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis (Lond) 2003;24:1291-300.
8. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995;55:1129-38.
9. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-54.
10. Maggiora P, Marchio S, Stella MC, et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998;16:2927-33.
11. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
12. Olivero M, Valente G, Bardelli A, et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 1999;82:640-3.
13. Santoro MM, Penengo L, Minetto M, et al. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 1998;17:741-9.
14. Gonzatti-Haces M, Seth A, Park M, et al. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p 140 protein-tyrosine kinases. Proc Natl Acad Sci USA 1988;85:21-5.
15. Santoro MM, Collesi C, Grisendi S, Gaudino G, ComogHo PM. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol 1996;16:7072-83.
16. Gaudino G, Follenzi A, Naldini L, et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 1994;13:3524-32.
17. Persons DA, Paulson RF, Loyd MR, et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet 1999;23:159-65.
18. Nishigaki K, Thompson D, Hanson C, Yugawa T, Ruscetti S. The envelope glycoprotein of friend spleen focus-forming virus covalently interacts with and constitutively activates a truncated form of the receptor tyrosine kinase Stk. J Virol 2001;75:7893-903.
19. Gaudino G, Avantaggiato V, Follenzi A, et al. The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene 1995;11:2627-37.
20. Ronsin C, Muscatelli F, Mattet MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993;8:1195-202.
21. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, et al. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 2000;29:147-56.
22. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997-2003.
23. Maggiora P, Lorenzato A, Fracchioli S, et al. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 2003;288:382-9.
24. Follenzi A, Allies LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000;25:217-22.
25. Waltz SE, Toms CL, McDowell SA, et al. Characterization of the mouse Ron/Stk receptor tyrosine kinase gene. Oncogene 1998;16:27-42.
26. Thompson EW, Paik S, Brunner N, et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992;150:534-44.
27. Di Renzo MF, Olivero M, Marione T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-55.
28. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in non-human cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19(Suppl 18):32S-40S.
29. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol 2001;153:1049-60.
30. Ji X, Woodard AS, Rimm DL, Fearon ER. Transcriptional defects underlie loss of E-cadherin expression in breast cancer. Cell Growth Differ 1997;8:773-8.
31. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613-8.
32. Batlle E, Sancho E, Franci C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2:84-9.
33. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
34. Perez-Moreno MA, Locascio A, Rodrigo I, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem 2001;276:27424-31.
35. Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7:1267-78.
36. Waltz SE, Eaton L, Toney-Earley K, et al. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Investig 2001;108:567-76.
37. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56:5079-86.
38. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-37.
39. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995;55:5195-9.
40. Hajra KM, Ji X, Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 1999;18:7274-9.
41. Fujita Y, Krause G, Scheffner M, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002;4:222-31.